A review of strategies for infarct size reduction during acute myocardial infarction
Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The repo...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Parviz, Yasir [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Cardiovascular revascularization medicine - Villemagne, Victor ELSEVIER, 2012, CRM, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:18 ; year:2017 ; number:5 ; pages:374-383 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.carrev.2017.02.004 |
|---|
| Katalog-ID: |
ELV035739738 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035739738 | ||
| 003 | DE-627 | ||
| 005 | 20230625205359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.carrev.2017.02.004 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017005000016.pica |
| 035 | |a (DE-627)ELV035739738 | ||
| 035 | |a (ELSEVIER)S1553-8389(17)30019-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.68 |2 bkl | ||
| 100 | 1 | |a Parviz, Yasir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A review of strategies for infarct size reduction during acute myocardial infarction |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. | ||
| 520 | |a Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. | ||
| 700 | 1 | |a Vijayan, Sethumadhavan |4 oth | |
| 700 | 1 | |a Lavi, Shahar |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Villemagne, Victor ELSEVIER |t Cardiovascular revascularization medicine |d 2012 |d CRM |g Amsterdam [u.a.] |w (DE-627)ELV000085782 |
| 773 | 1 | 8 | |g volume:18 |g year:2017 |g number:5 |g pages:374-383 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.carrev.2017.02.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.68 |j Gerontologie |j Geriatrie |q VZ |
| 951 | |a AR | ||
| 952 | |d 18 |j 2017 |e 5 |h 374-383 |g 10 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
y p yp |
|---|---|
| matchkey_str |
parvizyasirvijayansethumadhavanlavishaha:2017----:rveosrtgefrnacszrdcinuigctm |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
44.68 |
| publishDate |
2017 |
| allfields |
10.1016/j.carrev.2017.02.004 doi GBVA2017005000016.pica (DE-627)ELV035739738 (ELSEVIER)S1553-8389(17)30019-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.68 bkl Parviz, Yasir verfasserin aut A review of strategies for infarct size reduction during acute myocardial infarction 2017transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. Vijayan, Sethumadhavan oth Lavi, Shahar oth Enthalten in Elsevier Science Villemagne, Victor ELSEVIER Cardiovascular revascularization medicine 2012 CRM Amsterdam [u.a.] (DE-627)ELV000085782 volume:18 year:2017 number:5 pages:374-383 extent:10 https://doi.org/10.1016/j.carrev.2017.02.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 18 2017 5 374-383 10 045F 610 |
| spelling |
10.1016/j.carrev.2017.02.004 doi GBVA2017005000016.pica (DE-627)ELV035739738 (ELSEVIER)S1553-8389(17)30019-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.68 bkl Parviz, Yasir verfasserin aut A review of strategies for infarct size reduction during acute myocardial infarction 2017transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. Vijayan, Sethumadhavan oth Lavi, Shahar oth Enthalten in Elsevier Science Villemagne, Victor ELSEVIER Cardiovascular revascularization medicine 2012 CRM Amsterdam [u.a.] (DE-627)ELV000085782 volume:18 year:2017 number:5 pages:374-383 extent:10 https://doi.org/10.1016/j.carrev.2017.02.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 18 2017 5 374-383 10 045F 610 |
| allfields_unstemmed |
10.1016/j.carrev.2017.02.004 doi GBVA2017005000016.pica (DE-627)ELV035739738 (ELSEVIER)S1553-8389(17)30019-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.68 bkl Parviz, Yasir verfasserin aut A review of strategies for infarct size reduction during acute myocardial infarction 2017transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. Vijayan, Sethumadhavan oth Lavi, Shahar oth Enthalten in Elsevier Science Villemagne, Victor ELSEVIER Cardiovascular revascularization medicine 2012 CRM Amsterdam [u.a.] (DE-627)ELV000085782 volume:18 year:2017 number:5 pages:374-383 extent:10 https://doi.org/10.1016/j.carrev.2017.02.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 18 2017 5 374-383 10 045F 610 |
| allfieldsGer |
10.1016/j.carrev.2017.02.004 doi GBVA2017005000016.pica (DE-627)ELV035739738 (ELSEVIER)S1553-8389(17)30019-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.68 bkl Parviz, Yasir verfasserin aut A review of strategies for infarct size reduction during acute myocardial infarction 2017transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. Vijayan, Sethumadhavan oth Lavi, Shahar oth Enthalten in Elsevier Science Villemagne, Victor ELSEVIER Cardiovascular revascularization medicine 2012 CRM Amsterdam [u.a.] (DE-627)ELV000085782 volume:18 year:2017 number:5 pages:374-383 extent:10 https://doi.org/10.1016/j.carrev.2017.02.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 18 2017 5 374-383 10 045F 610 |
| allfieldsSound |
10.1016/j.carrev.2017.02.004 doi GBVA2017005000016.pica (DE-627)ELV035739738 (ELSEVIER)S1553-8389(17)30019-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.68 bkl Parviz, Yasir verfasserin aut A review of strategies for infarct size reduction during acute myocardial infarction 2017transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. Vijayan, Sethumadhavan oth Lavi, Shahar oth Enthalten in Elsevier Science Villemagne, Victor ELSEVIER Cardiovascular revascularization medicine 2012 CRM Amsterdam [u.a.] (DE-627)ELV000085782 volume:18 year:2017 number:5 pages:374-383 extent:10 https://doi.org/10.1016/j.carrev.2017.02.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 18 2017 5 374-383 10 045F 610 |
| language |
English |
| source |
Enthalten in Cardiovascular revascularization medicine Amsterdam [u.a.] volume:18 year:2017 number:5 pages:374-383 extent:10 |
| sourceStr |
Enthalten in Cardiovascular revascularization medicine Amsterdam [u.a.] volume:18 year:2017 number:5 pages:374-383 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Gerontologie Geriatrie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Cardiovascular revascularization medicine |
| authorswithroles_txt_mv |
Parviz, Yasir @@aut@@ Vijayan, Sethumadhavan @@oth@@ Lavi, Shahar @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000085782 |
| dewey-sort |
3610 |
| id |
ELV035739738 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035739738</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625205359.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.carrev.2017.02.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017005000016.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035739738</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1553-8389(17)30019-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.68</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Parviz, Yasir</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A review of strategies for infarct size reduction during acute myocardial infarction</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vijayan, Sethumadhavan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lavi, Shahar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Villemagne, Victor ELSEVIER</subfield><subfield code="t">Cardiovascular revascularization medicine</subfield><subfield code="d">2012</subfield><subfield code="d">CRM</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000085782</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:374-383</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.carrev.2017.02.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.68</subfield><subfield code="j">Gerontologie</subfield><subfield code="j">Geriatrie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2017</subfield><subfield code="e">5</subfield><subfield code="h">374-383</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Parviz, Yasir |
| spellingShingle |
Parviz, Yasir ddc 610 bkl 44.68 A review of strategies for infarct size reduction during acute myocardial infarction |
| authorStr |
Parviz, Yasir |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000085782 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.68 bkl A review of strategies for infarct size reduction during acute myocardial infarction |
| topic |
ddc 610 bkl 44.68 |
| topic_unstemmed |
ddc 610 bkl 44.68 |
| topic_browse |
ddc 610 bkl 44.68 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s v sv s l sl |
| hierarchy_parent_title |
Cardiovascular revascularization medicine |
| hierarchy_parent_id |
ELV000085782 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Cardiovascular revascularization medicine |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000085782 |
| title |
A review of strategies for infarct size reduction during acute myocardial infarction |
| ctrlnum |
(DE-627)ELV035739738 (ELSEVIER)S1553-8389(17)30019-2 |
| title_full |
A review of strategies for infarct size reduction during acute myocardial infarction |
| author_sort |
Parviz, Yasir |
| journal |
Cardiovascular revascularization medicine |
| journalStr |
Cardiovascular revascularization medicine |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
374 |
| author_browse |
Parviz, Yasir |
| container_volume |
18 |
| physical |
10 |
| class |
610 610 DE-600 610 VZ 44.68 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Parviz, Yasir |
| doi_str_mv |
10.1016/j.carrev.2017.02.004 |
| dewey-full |
610 |
| title_sort |
a review of strategies for infarct size reduction during acute myocardial infarction |
| title_auth |
A review of strategies for infarct size reduction during acute myocardial infarction |
| abstract |
Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. |
| abstractGer |
Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. |
| abstract_unstemmed |
Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
5 |
| title_short |
A review of strategies for infarct size reduction during acute myocardial infarction |
| url |
https://doi.org/10.1016/j.carrev.2017.02.004 |
| remote_bool |
true |
| author2 |
Vijayan, Sethumadhavan Lavi, Shahar |
| author2Str |
Vijayan, Sethumadhavan Lavi, Shahar |
| ppnlink |
ELV000085782 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.carrev.2017.02.004 |
| up_date |
2024-07-06T18:20:33.984Z |
| _version_ |
1803854842675855360 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035739738</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625205359.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.carrev.2017.02.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017005000016.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035739738</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1553-8389(17)30019-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.68</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Parviz, Yasir</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A review of strategies for infarct size reduction during acute myocardial infarction</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia–reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vijayan, Sethumadhavan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lavi, Shahar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Villemagne, Victor ELSEVIER</subfield><subfield code="t">Cardiovascular revascularization medicine</subfield><subfield code="d">2012</subfield><subfield code="d">CRM</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000085782</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:374-383</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.carrev.2017.02.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.68</subfield><subfield code="j">Gerontologie</subfield><subfield code="j">Geriatrie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2017</subfield><subfield code="e">5</subfield><subfield code="h">374-383</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4008284 |